Core Insights - SG Capital Management LLC reduced its holding in Haemonetics Corporation by 731,892 shares, resulting in a position value decline of approximately $59.1 million as of November 7, 2025 [1][2]. Company Overview - Haemonetics Corporation is a leading provider of medical devices and software for blood and plasma management, addressing critical needs in transfusion medicine and plasma collection through a diversified product portfolio and integrated technology platforms [5][6]. - The company generates revenue primarily from the sale of medical devices, disposables, and integrated software solutions to healthcare providers and plasma collection centers globally [6]. Financial Performance - For the trailing twelve months (TTM), Haemonetics reported revenue of $1.33 billion and net income of $168.19 million [4]. - The company's share price as of November 6, 2025, was $67.11, reflecting a 14.14% decline over the past year, underperforming the S&P 500 by 27.5 percentage points [4][10]. Recent Developments - Haemonetics reported a 5% decline in revenue for the fiscal second quarter, totaling $327 million, with a 1.8% drop when excluding foreign-currency exchange impacts and divestitures [8]. - Management's guidance for the full year's adjusted revenue indicates a potential decline of 1% to an increase of 2%, which is an improvement from previous guidance [9]. Investment Activity - Following the reduction in its stake, Haemonetics now accounts for only 0.8% of SG Capital's total 13F assets under management (AUM), down from 4.7% in the prior quarter [10]. - The market reacted positively to Haemonetics' results and guidance, with the share price increasing by 35% in the two days following the earnings release [11].